Sector News

Sanofi’s Plump tapped to head Takeda R&D from Cambridge base

December 18, 2014
Life sciences
The new president at Takeda has raided Sanofi for its new head of global R&D. And they’re putting their new top scientist in Cambridge, MA, which is becoming the world headquarters of drug research for much of the pharma industry.
 
Andrew “Andy” Plump has been lured to the top job at Takeda research after completing a stint as SVP of research and translational medicine at Sanofi, where he worked in Paris. Plump, though, has deep roots in Cambridge, where he got his B.S. at MIT before getting his M.D. at UC San Francisco and a PhD at Rockefeller University. After his education he worked as a VP of cardiovascular at Merck.
 
A Takeda spokesperson told Bloomberg that Plump will be based in Cambridge, MA, where the company has been reorganizing its oncology work. Takeda bought out Millennium, but recently dropped the iconic name.
 
The globalization of Takeda’s leadership began in earnest with the recent appointment of Christophe Weber as the new president, now in line to become the first non-Japanese CEO in 230 years – a fact that has ruffled more than a few feathers in Japan, where “foreigners” have not been welcome by former execs and shareholders. Weber was brought in to revamp Takeda as the company’s blockbuster Actos revenue has begun to disappear in the face of generic competition. U.S. president Doug Coles was recently ousted in the management shakeup that followed.  
 
Sanofi, meanwhile, is losing an American exec in the wake of Christopher Viehbacher’s stormy showdown with a French chairman of the board. 
 
Global pharma organizations like Pfizer, Novartis and others have been putting a growing emphasis on work around the Boston area, where biotech has been booming for years in neighborhoods close to MIT and Harvard. GlaxoSmithKline recently opened a new office to scout for deals in the area, following a similar move by J&J.
 
Takeda has had some success in the recent past, most notably the approval of vedolizumab for inflammatory bowel disease. But it’s also had late-stage failures for TAK-875, or fasiglifam, as well as their top cancer contender at Millennium. Those setbacks helped trigger a plan to carve $1 billion out of its budget and lay off thousands.
 
By John Carroll
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”